Detection of minimal residual disease by polymerase chain reaction of bcr/abl transcripts in chronic myelogenous leukaemia following allogeneic bone marrow transplantation

The prognostic significance of detecting minimal residual disease by polymerase chain reaction (PCR) amplification of bcr/abl mRNA transcripts was investigated in 27 bone marrow samples from 20 patients with Philadelphia chromosome (Ph¹) positive chronic myelogenous leukaemia (CML) in complete cytogenetic remission following allogeneic bone marrow transplantation. Sixteen were transplanted in first chronic phase, two were in second chronic phase, one was in accelerated phase and one was in blast crisis. All 20 achieved complete cytogenetic remission post transplant and 15 patients had detectable bcriabl mRNA by PCR from 2 to 22 months following the procedure. One of these patients had graft failure and one died from graft‐versus‐host‐disease at 7 months. Of the remaining 13 PCR‐positive patients, only one (8%) relapsed after 23 months: the other 12 were alive and still in remission after a median follow‐up of 16 + months (ranging 5+ to 29+ months). Five patients were PCR negative: all are alive in complete clinical and cytogenetic remission at lo +, 11 +, 19 +, 25+ and 25+ months post transplant. In this study, detection of subclinical Ph^l‐positive cells by PCR was not associated with imminent clinical or cytogenetic relapse. Since late recurrence may potentially occur, long‐term follow‐up is required to definitely determine the prognostic value of the PCR assay.